Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16932330 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL2516271 | 0.86 | L3MBTL1 (0.52) | L3MBTL1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL25970364 | 0.86 | OPRK1 (0.49) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL2516270 | 0.86 | L3MBTL1 (0.52) | L3MBTL1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL987913 | 0.83 | KMT2A (0.44) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL10315708 | 0.83 | KMT2A (0.44) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL84195 | 0.83 | KMT2A (0.44) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL25181400 | 0.81 | EPOR (0.52) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL30057999 | 0.81 | KMT2A (0.46) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL16934693 | 0.81 | PTPN1 (0.45) | L3MBTL1KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3894416-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | Global Blood Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3323814-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3323814-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2018-05-23 | — | — | EP | disclosed |
| EP-3323814-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | L3MBTL1 2439/4885MAPT 4429/4885KMT2A 4244/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | L3MBTL1 3480/4885MAPT 4182/4885KMT2A 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.